AI Stock Analysis - Cabaletta Bio (CABA)
Analysis generated January 25, 2026.
Cabaletta Bio is a biotechnology company focused on discovering and developing engineered T cell therapies for patients with B cell-mediated autoimmune diseases and other serious conditions. The company aims to harness the power of T cells in order to address diseases that current therapies have been unable to effectively treat.
Stock Alerts - Cabaletta Bio (CABA)
 |
Cabaletta Bio | March 10 Price is up by 6.9% in the last 24h. |
|
Cabaletta Bio | March 5 Price is down by -6.1% in the last 24h. |
|
Cabaletta Bio | February 27 Price is down by -6.3% in the last 24h. |
|
Cabaletta Bio | February 26 Price is down by -7.3% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Cabaletta Bio
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 14 | Sign up | Sign up | Sign up |
| Sentiment | 75 | Sign up | Sign up | Sign up |
| Webpage traffic | 8,000 | Sign up | Sign up | Sign up |
| Employee Rating | 90 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 68 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 3,606 | Sign up | Sign up | Sign up |
| X Followers | 540 | Sign up | Sign up | Sign up |
| X Mentions | 42 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 78 | Sign up | Sign up | Sign up |
| Linkedin Employees | 180 | Sign up | Sign up | Sign up |
About Cabaletta Bio
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases.
| Price | $3.32 |
| Target Price | Sign up |
| Volume | 1,612,361 |
| Market Cap | $315M |
| Year Range | $1.33 - $3.61 |
| Dividend Yield | 0% |
| Analyst Rating | 78% buy |
| Industry | Biotechnology |
In the news
Here’s Why Jacob Funds Established a Position in Cabaletta Bio (CABA)February 18 - Yahoo Entertainment |
|
 |
Is Cabaletta Bio (CABA) Outperforming Other Medical Stocks This Year?January 26 - Yahoo |
 |
Cabaletta Bio: Do You Buy With The Insiders?January 26 - SeekingAlpha |
|
Assessing Cabaletta Bio (CABA) Valuation After Insider Buying And FDA Clearance For Automated CAR T ManufacturingJanuary 26 - Yahoo |
 |
Cabaletta Bio announces 2026 strategic prioritiesJanuary 12 - Thefly.com |
Cabaletta Bio Announces 2026 Strategic PrioritiesJanuary 12 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 0 | 350,000 | -350,000 | -45M | -44M | -0.440 |
| Q2 '25 | 0 | 470,000 | -470,000 | -45M | -44M | -0.730 |
| Q1 '25 | 0 | 490,000 | -490,000 | -36M | -35M | -0.650 |
| Q4 '24 | 1.6M | 470,000 | -470,000 | -33M | -31M | -0.650 |
| Q3 '24 | 0 | 420,000 | -420,000 | -31M | -30M | -0.620 |
Insider Transactions View All
| Gerard Michael filed to buy 6,600 shares at $2.3. January 21 '26 |
| Bollard Catherine filed to buy 5,405 shares at $2.3. January 21 '26 |
| Chang David J. filed to buy 8,800 shares at $2.3. January 21 '26 |
| Simon Mark filed to buy 147,205 shares at $2.3. January 21 '26 |
| Nichtberger Steven filed to buy 1,031,483 shares at $2.2. January 21 '26 |
Similar companies
Read more about Cabaletta Bio (CABA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Cabaletta Bio
The Market Cap of Cabaletta Bio is $315M.
Currently, the price of one share of Cabaletta Bio stock is $3.32.
The CABA stock price chart above provides a comprehensive visual representation of Cabaletta Bio's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Cabaletta Bio shares. Our platform offers an up-to-date CABA stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Cabaletta Bio (CABA) does not offer dividends to its shareholders. Investors interested in Cabaletta Bio should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Cabaletta Bio are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
